'Centre, not states should pay for COVID vaccine': Arvind Subramanian recommends free jabs to avoid politicisation

-

Former chief economic adviser Arvind Subramanian said that India's vaccination strategy is "complicated and politicised", and asserted that it is the Central Government, and not states, that should bear the "fiscal costs of vaccines".

Subramanian listed three reasons to support his argument: First, he stated that the "virus doesn't respect state borders". Secondly, he added, the Centre has better access to resources than states. And thirdly, the former CEA added, "Fiscal 'costs' are trivial compared to lives saved and economic activity preserved."

In a series of tweets, Subramanian also said that free vaccination is the only way to avoid politicisation of the COVID-19 vaccine and that the government should pay manufacturers a reasonable price for the vaccine.

Subramanian's remarks have come amid a row over the pricing of the Covishield vaccine.

The Centre had on Saturday said that it would pay only Rs 150 per dose of Covishield to Pune-based Serum Institute of India (SII) after the company told a newspaper that both states and Centre would be charged Rs 400 a dose for new contracts of the Covishield vaccine, an Indian version of the Oxford-AstaZeneca COVID-19 vaccine.

Without making any direct reference to the row, Subramanian said the Centre should pay manufacturers a reasonable price for the vaccine.

"This is not the time for haggling and creating uncertainty for the private sector, domestic or foreign," the former CEA said on the vaccine pricing.

There has been a lot of confusion over the price of vaccines in India after the government allowed both states as well as private hospitals to procure the vaccine directly from manufacturers for the next phase of vaccination, when everyone above the age of 18 will be eligible for a shot from 1 May.

According to reports, while the Centre procured the vaccine at Rs 150 per dose, for the next phase of inoculation, states will be charged Rs 400 for a dose of the Covishield vaccine, private players have to shell out Rs 600 a dose for the same vaccine.

This, experts have warned, will make the vaccine out of reach for several individuals, especially the economically weaker section of the population.

As per a report in report in The Indian Express, at a cost of Rs 600 per dose, Indians will end up paying the highest price in the world for the vaccine developed by Oxford and AstraZeneca and manufactured in India by the SII as Covishield.

The SII, however, later clarified, according to another Indian Express article, that the cost of Rs 600 a dose for Covishield is for a limited stock of the vaccine and shouldn't be compared with international prices.

Subramanian said that this differential pricing is not just unethical but would also difficult to implement. "There should be only one price for vaccine jabs all over India. That price should be zero. So, vaccines should be free for all. Differentiation and complexity are unethical, unnecessary, and difficult to implement. Free vaccines for all will avoid vaccine politicisation," he said.

Besides, the pricing issues, India's nationwide vaccination programme is already facing troubles due to the short supply of vaccines, mismanagement of crowds at centres, cancellation of vaccine appointments made on the Cowin app without notice.

These issues, experts, have warned will only aggravate once it opens for all above the age of 18 from 1 May.

 



from Firstpost India Latest News https://ift.tt/3dNyp2b
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more